Literature DB >> 22044226

Amphipathic properties of HIV-1 gp41 fusion inhibitors.

Miriam Gochin1, Guangyan Zhou.   

Abstract

Small molecule inhibition of HIV fusion has been an elusive goal, despite years of effort by both pharmaceutical and academic laboratories. In this review, we will discuss the amphipathic properties of both peptide and small molecule inhibitors of gp41-mediated fusion. Many of the peptides and small molecules that have been developed target a large hydrophobic pocket situated within the grooves of the coiled coil, a potential hotspot for inhibiting the trimer of hairpin formation that accompanies fusion. Peptide studies reveal molecular properties required for effective inhibition, including elongated structure and lipophilic or amphiphilic nature. The characteristics of peptides that bind in this pocket provide features that should be considered in small molecule development. Additionally, a novel site for small molecule inhibition of fusion has recently been suggested, involving residues of the loop and fusion peptide. We will review the small molecule structures that have been developed, evidence pointing to their mechanism of action and strategies towards improving their affinity. The data points to the need for a strongly amphiphilic character of the inhibitors, possibly as a means to mediate the membrane - protein interaction that occurs in gp41 in addition to the protein - protein interaction that accompanies the fusion-activating conformational transition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22044226      PMCID: PMC3219813          DOI: 10.2174/156802611798808488

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  111 in total

Review 1.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

2.  Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.

Authors:  Gary Frey; Sophia Rits-Volloch; X-Q Zhang; Robert T Schooley; Bing Chen; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

3.  Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.

Authors:  Kun Liu; Hong Lu; Ling Hou; Zhi Qi; Cátia Teixeira; Florent Barbault; Bo-Tao Fan; Shuwen Liu; Shibo Jiang; Lan Xie
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.

Authors:  Andrew Vaillant; Jean-Marc Juteau; Hong Lu; Shuwen Liu; Carol Lackman-Smith; Roger Ptak; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions.

Authors:  Victor Buzon; Ganesh Natrajan; David Schibli; Felix Campelo; Michael M Kozlov; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

6.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Authors:  Douglas S Watson; Francis C Szoka
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

8.  Palmitic acid analogs exhibit nanomolar binding affinity for the HIV-1 CD4 receptor and nanomolar inhibition of gp120-to-CD4 fusion.

Authors:  Elena E Paskaleva; Jing Xue; David Y-W Lee; Alexander Shekhtman; Mario Canki
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

Review 9.  Targeting cell entry of enveloped viruses as an antiviral strategy.

Authors:  Elodie Teissier; François Penin; Eve-Isabelle Pécheur
Journal:  Molecules       Date:  2010-12-30       Impact factor: 4.411

10.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

View more
  8 in total

1.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

2.  Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.

Authors:  Guangyan Zhou; Dong Wu; Beth Snyder; Roger G Ptak; Harmeet Kaur; Miriam Gochin
Journal:  J Med Chem       Date:  2011-10-03       Impact factor: 7.446

3.  Enhanced potency of bivalent small molecule gp41 inhibitors.

Authors:  Vladimir Sofiyev; Hardeep Kaur; Beth A Snyder; Priscilla A Hogan; Roger G Ptak; Peter Hwang; Miriam Gochin
Journal:  Bioorg Med Chem       Date:  2016-11-19       Impact factor: 3.641

Review 4.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

5.  Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching.

Authors:  Shidong Chu; Miriam Gochin
Journal:  Bioorg Med Chem Lett       Date:  2013-07-22       Impact factor: 2.823

6.  Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes.

Authors:  Longlong Si; Kun Meng; Zhenyu Tian; Jiaqi Sun; Huiqiang Li; Ziwei Zhang; Veronica Soloveva; Haiwei Li; Ge Fu; Qing Xia; Sulong Xiao; Lihe Zhang; Demin Zhou
Journal:  Sci Adv       Date:  2018-11-21       Impact factor: 14.136

7.  De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.

Authors:  Chao Wang; Lei Zhao; Shuai Xia; Tianhong Zhang; Ruiyuan Cao; Guodong Liang; Yue Li; Guangpeng Meng; Weicong Wang; Weiguo Shi; Wu Zhong; Shibo Jiang; Keliang Liu
Journal:  J Med Chem       Date:  2018-09-19       Impact factor: 7.446

8.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.